/
Cardiovascular
Peripheral Arterial Disease
24
Pipeline Programs↗
29
Active Trials↗
35
Companies Involved↗
Peripheral Arterial Disease is an emerging landscape with 24 programs across 35 companies. The most active players are VivaCell Biotechnology España, Sirius Therapeutics Co., Ltd.. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 1
No programs
Phase 24
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
21 of 23 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.
Analysis
Trial Status
107
clinical trials
Completed51 · 48%
Recruiting17 · 16%
Unknown status13 · 12%
Terminated9 · 8%
Not yet recruiting7 · 7%
Withdrawn5 · 5%
Other5 · 5%
Clinical Trials
Trial Activity
107 trials
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)
Recruiting·—·N/A·NCT07672249·98 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)